Your session is about to expire
← Back to Search
Treatment for Malignant Pleural Mesothelioma (BASECAMP-1 Trial)
Summary
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
- Malignant Pleural Mesothelioma
- Solid Tumors
- Ovarian Tumors
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Mesothelioma
- Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger